Strides Arcolab gets USFDA nod for rifampicin injection

New Delhi, May 23 (UNI) Strides Arcolab today said it has received the ANDA approval from the US Food and Drug Administration for Rifampicin Injection USP in 600 mg/vial.

'It has received the approval for Rifampicin. The product is licenced to Akron-Strides, a JV between strides and Akron,'' a company statement said.

Strides manufactures pharmaceutical formulations in various doses forms, including capsules, tablets, liquid injectables and has a major presence in developing countries like Africa, Latin America, Asia, Canada, and part of Europe.

UNI SR AK GC1922